These data, however, cannot fully justify the observed amelioration of steatosis, suggesting that there are further factors involved, regarding the hepatoprotective properties of SGLT2-is in MASLD patients [27]. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.